A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2996 participants.

Also called NCT01137474

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,996 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01137474
  • EudraCT 2010-019797-32
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Colombia, Czechia, Denmark, Finland, Germany, Hungary, India, Mexico, Peru, Poland, Puerto Rico, Romania, Russia, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01137474. Randomized; triple masking; primary purpose treatment. Start 2010-07 (registry gives no type); primary completion 2013-02 (actual). Results posted on 2014-05-01.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Placebo-matching dapagliflozin
Lead sponsor
AstraZeneca (class: industry)
Collaborator
Bristol-Myers Squibb (class: industry)

Record details

Record id
cardio:ct-nct01137474
Content hash
fb7208ab172406b937f8fbe3da38caf174fdf812704719c11afd0c392d729f39